Immunocine Cancer Center

Your Greatest Defense is Within You

Immunocine was founded with the sole purpose of bringing a revolutionary immunotherapy to cancer patients unable to participate in ongoing FDA clinical trials.

The Immunocine Dendritic Cell Treatment (IDCT) protocol is the first to “Double Load” the patient’s Dendritic Cells with their extracted cancer cells. This simulates a viral-like infection and initiates specific T cells to seek and destroy the cancer cells throughout the patient’s body.

Backed by 16 years of research and ongoing FDA Clinical Trials, the IDCT protocol is a less invasive, more precise way to treat multiple types of cancer.

Visit our website to see if you are eligible to apply for treatment.